… SARS-CoV. Furthermore, we demonstrate the therapeutic potential of the nanobody against
SARS-CoV-2 and the … This naturally elicited bispecific monomeric nanobody establishes an …

… potently neutralizes both SARS-CoV-1 and WT SARS-CoV-2. Based … bispecific nanobody
dimer (2-3-Fc) by fusing aSA3-Fc to aRBD-2, a previously identified broad-spectrum nanobody …

… the screen of a panel of SARS-CoV-2 receptor-binding domain (RBD) targeted nanobodies
(Nbs) from a … Neutralization of SARS-CoV-2 VOC and VOI by monomeric and bivalent Nbs. a …

… nanobody (sybody) pair (Sb#15 and Sb#68) that can bind 27 simultaneously to the SARS-CoV-2 …
Two spatially-discrete epitopes identified by cryo-EM translated 29 into the rational …

… SARS-CoV-2 receptor-binding domain (RBD). Here, we report five X-ray crystal structures of
sybodies (synthetic nanobodies) … These sybodies behaved as monomers by size-exclusion …

… As monomers, they often lack the high binding affinity required for therapeutic use. In this …
Another study discovered three new bispecific nanobodies (Nb15-Fc, Nb22-Fc, and Nb31-Fc) …

… Monomeric 1 × Nb 15 exhibited low … the monomer but comparable potency among the
multimers with IC 50 values of 2.8, 3.5, and 2.3 ng/ml (11, 9.0, and 4.3 pM), respectively (Figure 2C…

… They may also be employed as integrant for creating bispecific or multispecific antibodies (…
of oligomeric nanobodies, relative to monomeric nanobodies against MERS coronavirus RBD…

… Moreover, strategic linking of nanobodies into bivalent, trivalent, bispecific and tri-specific …
100-fold more potent than their monomeric nanobodies in neutralizing the SARS-CoV-2 …

… As such, nanobodies could exist as monomeric single-domain antibodies with high
solubility in aqueous solution. In addition, it had been shown that the hydrophilic amino acid …